ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 232 filers reported holding ACADIA PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.85 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,185,000 | -5.8% | 56,798 | +8.1% | 0.00% | – |
| Q2 2023 | $1,258,000 | +34.8% | 52,522 | +6.0% | 0.00% | – |
| Q1 2023 | $933,000 | -18.4% | 49,566 | -31.0% | 0.00% | – |
| Q4 2022 | $1,144,000 | -0.6% | 71,801 | +2.1% | 0.00% | – |
| Q3 2022 | $1,151,000 | +3.6% | 70,292 | -10.9% | 0.00% | – |
| Q2 2022 | $1,111,000 | -40.9% | 78,897 | +1.6% | 0.00% | – |
| Q1 2022 | $1,880,000 | -15.2% | 77,635 | -18.3% | 0.00% | -100.0% |
| Q4 2021 | $2,218,000 | +61.2% | 95,043 | +14.8% | 0.00% | – |
| Q3 2021 | $1,376,000 | -31.7% | 82,818 | +0.3% | 0.00% | -100.0% |
| Q2 2021 | $2,015,000 | -49.7% | 82,597 | -46.8% | 0.00% | 0.0% |
| Q1 2021 | $4,008,000 | -61.1% | 155,274 | -19.4% | 0.00% | -66.7% |
| Q4 2020 | $10,303,000 | +35.5% | 192,742 | +4.6% | 0.00% | 0.0% |
| Q3 2020 | $7,601,000 | -24.6% | 184,285 | -11.4% | 0.00% | -25.0% |
| Q2 2020 | $10,078,000 | +22.6% | 207,929 | +6.9% | 0.00% | 0.0% |
| Q1 2020 | $8,220,000 | +38.8% | 194,543 | +40.5% | 0.00% | +100.0% |
| Q4 2019 | $5,923,000 | -1.9% | 138,464 | -17.5% | 0.00% | 0.0% |
| Q3 2019 | $6,038,000 | +115.3% | 167,760 | +59.8% | 0.00% | +100.0% |
| Q2 2019 | $2,805,000 | -5.5% | 104,967 | -5.1% | 0.00% | 0.0% |
| Q1 2019 | $2,969,000 | +91.2% | 110,562 | +15.1% | 0.00% | 0.0% |
| Q4 2018 | $1,553,000 | -24.4% | 96,048 | -2.8% | 0.00% | 0.0% |
| Q3 2018 | $2,053,000 | +42.2% | 98,833 | +4.5% | 0.00% | 0.0% |
| Q2 2018 | $1,444,000 | -10.9% | 94,570 | +31.2% | 0.00% | 0.0% |
| Q1 2018 | $1,620,000 | -11.9% | 72,080 | +18.2% | 0.00% | 0.0% |
| Q4 2017 | $1,838,000 | -27.2% | 61,002 | -9.0% | 0.00% | 0.0% |
| Q3 2017 | $2,526,000 | +40.5% | 67,048 | +4.0% | 0.00% | 0.0% |
| Q2 2017 | $1,798,000 | -7.5% | 64,461 | +14.1% | 0.00% | 0.0% |
| Q1 2017 | $1,943,000 | +55.8% | 56,499 | +30.7% | 0.00% | 0.0% |
| Q4 2016 | $1,247,000 | -90.6% | 43,213 | -89.7% | 0.00% | -85.7% |
| Q3 2016 | $13,286,000 | -33.3% | 417,668 | -31.9% | 0.01% | -41.7% |
| Q2 2016 | $19,909,000 | -10.1% | 613,300 | -22.6% | 0.01% | -14.3% |
| Q1 2016 | $22,155,000 | +214.7% | 792,414 | +301.2% | 0.01% | +180.0% |
| Q4 2015 | $7,041,000 | +4823.8% | 197,516 | +4471.1% | 0.01% | – |
| Q3 2015 | $143,000 | +1091.7% | 4,321 | +1340.3% | 0.00% | – |
| Q2 2015 | $12,000 | -83.3% | 300 | -86.4% | 0.00% | – |
| Q1 2015 | $72,000 | -62.1% | 2,200 | -63.2% | 0.00% | – |
| Q4 2014 | $190,000 | +41.8% | 5,981 | +11.0% | 0.00% | – |
| Q3 2014 | $134,000 | +2580.0% | 5,390 | +2595.0% | 0.00% | – |
| Q2 2014 | $5,000 | -82.8% | 200 | -83.3% | 0.00% | – |
| Q1 2014 | $29,000 | -47.3% | 1,200 | -45.5% | 0.00% | – |
| Q4 2013 | $55,000 | +34.1% | 2,200 | +44.5% | 0.00% | – |
| Q3 2013 | $41,000 | +925.0% | 1,522 | +661.0% | 0.00% | – |
| Q2 2013 | $4,000 | – | 200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |